Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data of Tumor-Targeted Immune Cell Agonists (TICAs™) in the Journal for ImmunoTherapy of Cancer

Rhea-AI Summary

Bicycle Therapeutics (NASDAQ:BCYC) announced the publication of preclinical studies on its innovative synthetic tumor-targeted immune cell agonists (TICAs) in the Journal for ImmunoTherapy of Cancer. The research highlights the potential of TICAs to enhance anticancer immunity through the modulation of CD137. Findings demonstrated that TICAs could efficiently co-stimulate human immune cells and eliminate tumors in preclinical models. The company plans to initiate a clinical trial for its lead TICA, BT7480, within the year, showcasing its commitment to advancing cancer immunotherapy.

Positive

• Publication of preclinical study results in a reputable journal, indicating scientific validation.
• Demonstrated efficacy of TICAs in activating immune responses against tumors, suggesting potential for clinical success.
• Plans to initiate clinical trials for lead TICA, BT7480, within the year, indicating progress in development.

Negative

• None.

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle^®) technology, today announced that an article highlighting preclinical studies of Bicycle’s novel, fully synthetic Bicycle systemic immune cell agonists and tumor-targeted immune cell agonists (TICAs™) was published in the Journal for ImmunoTherapy of Cancer (JITC). The article, titled “Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist” is available online via this link.

“The data published in JITC describe the application of Bicycle’s unique technology to produce a new class of potential immuno-oncology therapies: tumor-targeted immune cell agonists, or TICAs,” said Nicholas Keen, Ph.D., Chief Scientific Officer of Bicycle Therapeutics. “In contrast to immune checkpoint inhibitors, the use of antibodies as agonists of immune costimulatory receptors as cancer therapeutics has largely failed. Here we demonstrate the discovery of small, chemically synthetic Bicycles that bind to key co-stimulatory receptors and that can be coupled in a modular manner to tumor antigen binding Bicycles to produce tumor localized receptor agonism. We look forward to initiating a clinical trial for our lead TICA program, BT7480, this year.”

The article outlines the work Bicycle is undertaking to unlock a new method of cancer immunotherapy via small molecule agonism of TNF superfamily receptors. In the studies, TICAs were evaluated in a suite of in vitro and in vivo assays to characterize the pharmacology and mechanism of action. Results showed that by linking a costimulatory receptor (e.g., CD137) targeting Bicycle to a tumor antigen (e.g., EphA2), targeting Bicycle potent agonists were created, which activated the costimulatory receptor selectively in the presence of tumor cells expressing that antigen. An EphA2/CD137 TICA efficiently co-stimulated human peripheral blood mononuclear cells in vitro in the presence of EphA2-expressing tumor cell lines, as measured by an increased secretion of interferon γ and interleukin-2. Treatment of C57/Bl6 mice (transgenic for the human CD137 extracellular domain, huCD137) bearing EphA2-expressing MC38 tumors resulted in increased infiltration of CD8+ T cells, the elimination of tumors, and generation of immunological memory. Tumor target-dependent CD137 agonism using TICAs afforded elimination of tumors in preclinical models using only intermittent dosing, suggesting the potential for a wide therapeutic index in humans.

About Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles^®, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle’s lead product candidate, BT1718, a Bicycle Toxin Conjugate (BTC) that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is also evaluating BT5528, a second-generation BTC targeting EphA2, in a Company-sponsored Phase I/II study. BT8009 is a BTC targeting Nectin-4, a well-validated tumor antigen, and is also currently being evaluated a Company-sponsored Phase I/II trial. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.

Forward-Looking Statements

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the discovery and development of potential product candidates using Bicycle’s technology; anticipated advancement of preclinical development efforts and initiation and progression of clinical trials; and the therapeutic potential for Bicycles in various disease applications. Bicycle may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as to Bicycle’s and its collaboration partners’ abilities to meet other anticipated deadlines and milestones, presented by the ongoing COVID-19 pandemic; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of Bicycle’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of Bicycle’s product candidates; expectations for regulatory approvals to conduct trials or to market products;; and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled “Risk Factors” in our Annual Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 5, 2020, as well as in other filings Bicycle may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Bicycle expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210126005609/en/

FAQ

What are TICAs and how do they relate to Bicycle Therapeutics?

TICAs, or tumor-targeted immune cell agonists, are a novel class of immuno-oncology therapies developed by Bicycle Therapeutics aimed at enhancing anticancer immunity.

What were the key findings from the recent Bicycle Therapeutics publication?

The publication reported that TICAs effectively co-stimulated immune cells and induced tumor elimination in preclinical models, suggesting promising therapeutic potential.

When will Bicycle Therapeutics initiate clinical trials for BT7480?

Bicycle Therapeutics plans to initiate clinical trials for its lead TICA, BT7480, within the current year.

What is the significance of the article published in the Journal for ImmunoTherapy of Cancer?

The article provides validation of Bicycle's TICA technology and its potential to improve cancer immunotherapy outcomes, which may impact future clinical application.

How does Bicycle's technology differ from traditional cancer therapies?

Bicycle's technology focuses on small synthetic peptides that target immune receptors, offering a novel approach compared to conventional immune checkpoint inhibitors.